CoChat

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

Open access

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life standard of care (SOC) in triple-class exposed (received at least a PI, IMiD, and anti-CD38 mAb) patients with relapsed/refractory MM (RRMM). Patients ( N = 248; ECOG performance status of 0–1, ≥3 prior lines of therapy or double refractory to a PI and IMiD) were treated with median 4.0 (range, 1–20) cycles of SOC therapy. Overall response rate was 29.8% (95% CI: 24.2–36.0). Median progression-free survival (PFS) and median overall survival (OS) were 4.6 (95% CI: 3.9–5.6) and 12.4 months (95% CI: 10.3–NE). Treatment-emergent adverse events (TEAEs) were reported in 83.5% of patients (52.8% grade 3/4). Altogether, 107 deaths occurred, due to progressive disease ( n = 74), TEAEs ( n = 19), and other reasons ( n = 14). The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41375-022-01531-2

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study disposition. aEnrolled patients are those who signed informed consent and were formally enrolled into the study. bTreated patients are those who were enrolled in the study and received at least one standard of care treatment.
Fig. 1 Study disposition. aEnrolled patients are those who signed informed consent and were formally enrolled into the study. bTreated patients are those who were enrolled in the study and received at least one standard of care treatment.CC BY · PubMed Central
Fig. 2 Kaplan–Meier plots for survival outcomes. Progression-free survival and overall survival based on RRC assessment in all patients (A, B) and in patients who achieved VGPR or better versus those who did not (C, D). RRC Response Review Committee, SOC standard of care, VGPR very good partial response.
Fig. 2 Kaplan–Meier plots for survival outcomes. Progression-free survival and overall survival based on RRC assessment in all patients (A, B) and in patients who achieved VGPR or better versus those who did not (C, D). RRC Response Review Committee, SOC standard of care, VGPR very good partial response.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 295

Metadata

Authors
Mateos, M.-V., Weisel, K., De Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., Cavo, M., Vij, R., Lindsey-Hill, J., Dytfeld, D., Angelucci, E., Perrot, A., Benjamin, R., van de Donk, N. W. C. J., Ocio, E. M., Scheid, C., Gay, F., Roeloffzen, W., Rodriguez-Otero, P., Broijl, A., Potamianou, A., Sakabedoyan, C., Semerjian, M., Keim, S., Strulev, V., Schecter, J. M., Vogel, M., Wapenaar, R., Nesheiwat, T., San-Miguel, J., Sonneveld, P., Einsele, H., & Moreau, P.
Affiliations
  • University Medical Center Hamburg-Eppendorf (DE)
  • University Hospital Heidelberg (DE)
  • Universitair Ziekenhuis Leuven (BE)
  • Inserm (FR)
  • Washington University in St. Louis (US)
  • Nottingham University Hospitals NHS Trust (GB)
  • Poznan University of Medical Sciences (PL)
  • Ospedale Policlinico San Martino (IT)
  • Centre Hospitalier Universitaire de Toulouse (FR)
  • King's College London (GB)
  • Universidad de Cantabria (ES)
  • University of Cologne (DE)
  • University of Turin (IT)
  • University Medical Center Groningen (NL)
  • Erasmus MC Cancer Institute (NL)
  • Janssen (Germany) (DE)
  • Janssen (France) (FR)
  • Janssen (Belgium) (BE)
  • Janssen Research & Development (United States) (US)
  • Legend Biotech (United States) (US)
  • Universitätsklinikum Würzburg (DE)
  • Nantes Université (FR)
Venue
Leukemia
Published
2022-03-24
Volume
36
Issue
5
Pages
1371-1376
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W4221027512
Cited by
252
References
10
Citations by year
2026: 38 · 2025: 63 · 2024: 77 · 2023: 56 · 2022: 17
FWCI
38.73
Type
journal article
Language
en
Open access
Licence
Locations
  • Leukemia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, cc-by)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
  • Lirias (KU Leuven) (submittedVersion, cc-by)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
  • PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
relapsed/refractory multiple myeloma, standard of care, proteasome inhibitors, immunomodulators, anti-CD38 monoclonal antibody, real-world treatment patterns, progression-free survival, overall survival, treatment-emergent adverse events, heavily pretreated patients
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Multiple Myeloma, Prospective Studies, Standard of Care, Proteasome Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. https://app.cochat.ai/papers/10.1038/s41375-022-01531-2
The paper
Mateos, M.-V., Weisel, K., De Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., Cavo, M., Vij, R., Lindsey-Hill, J., Dytfeld, D., Angelucci, E., Perrot, A., Benjamin, R., van de Donk, N. W. C. J., Ocio, E. M., Scheid, C., Gay, F., Roeloffzen, W., Rodriguez-Otero, P., . . . Moreau, P. (2022). LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. https://doi.org/10.1038/s41375-022-01531-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.